沙库巴曲缬沙坦联合β受体阻滞剂在老年冠心病合并心力衰竭患者中的应用观察  

Observation on Application of Sacubitril Valsartan Combined withβReceptor Blocker in Elderly Patients with Coronary Heart Disease and Heart Failure

作　　者：雷红 Lei Hong(Internal medicine Department,Liandu District People's Hospital,Lishui 323006,Zhejiang Province,China)

机构地区：[1]丽水市莲都区人民医院内科,浙江丽水323006

出　　处：《中国社区医师》2024年第25期10-12,共3页Chinese Community Doctors

摘　　要：目的:分析沙库巴曲缬沙坦联合β受体阻滞剂在老年冠心病合并心力衰竭患者中的应用效果。方法:选取2022年1—12月莲都区人民医院收治的冠心病合并心力衰竭患者78例作为研究对象,随机分为对照组(39例)和观察组(39例)。对照组给予β受体阻滞剂治疗,观察组在对照组基础上给予沙库巴曲缬沙坦钠片治疗。比较两组临床疗效、心功能、血清因子水平、不良反应发生情况。结果:观察组治疗有效率高于对照组(P=0.013)。治疗前,两组左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)对比,无统计学差异(P>0.05);治疗后,两组LVESD、LVEDD小于治疗前,且观察组小于对照组,两组LVEF高于治疗前,且观察组高于对照组(P<0.05)。治疗前,两组氨基末端前B类利钠肽(NT-proBNP)、心肌肌钙蛋白(cTnI)水平比较,无统计学差异(P>0.05);治疗后,两组NT-proBNP、cTnI水平低于治疗前,且观察组低于对照组(P<0.05)。两组不良反应发生率对比,无统计学差异(P>0.05)。结论:沙库巴曲缬沙坦联合β受体阻滞剂在老年冠心病合并心力衰竭患者中的应用效果显著,可改善患者心功能,降低血清指标,且安全性较高。Objective:To analyze the application of sacubitril valsartan combined withβreceptor blocker in elderly patients with coronary heart disease and heart failure.Methods:Seventy-eight patients with coronary heart disease and heart failure admitted to Liandu District People's Hospital from January 2022 to December 2022 were selected as the study subjects.They were randomly divided into control group(39 cases)and observation group(39 cases).The control group was treated withβreceptor blocker and the observation group was treated with sacubitril valsartan sodium tablets on the basis of control group.The clinical efficacy,cardiac function,levels of serum factors and occurrence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in the observation group was higher than that in the control group(P=0.013).Before treatment,there was no significant difference in left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)between the two groups(P>0.05).After treatment,the LVESD and LVEDD in the two groups were lower than those before treatment,and these indexes in the observation group were lower than those in the control group,while the LVEF in the two groups was higher than that before treatment,and this index in the observation group was higher than that in the control group(P<0.05).Before treatment,there was no significant difference in the levels of N-terminal pro B-type natriuretic peptide(NT-proBNP)and cardiac troponin(cTnI)between the two groups(P>0.05).After treatment,the levels of NT-proBNP and cTnI in the two groups were lower than those before treatment,and the levels in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Sacubitril valsartan combined withβreceptor blocker has a significant effect in elderly patients with coronary heart disease and heart fai

关 键 词：沙库巴曲缬沙坦 Β受体阻滞剂 冠心病 心力衰竭 

分 类 号：R541.4[医药卫生—心血管疾病]